Team & Advisors
A focused founding team with deep expertise in proteomics, aging biology, multi-omics, and population health — supported by fractional advisors in clinical development and regulatory affairs.
CW
Domain expert in proteomics, population health, and preventive medicine. Conceived and chaired the UK Biobank Pharma Proteomics Project (UKB-PPP) — a 13-company consortium that measured 2,932 plasma proteins across 54,000 samples and secured $47M in competitive funding, including $26.5M from the UK Government to expand to 600,000 samples. Flagship paper in Nature, 2023. 60+ publications, h-index 44, 15,000+ citations.
- Founder & Managing Director, Ignition Scientific (2025–Present) — advising NIH All of Us (consortium formation), Eli Lilly (biobanks & multi-omics strategy), AbbVie, Danaher Corporation, Flagship Pioneering, Michael J. Fox Foundation, Helix Inc., and IMU Biomedicines
- Head of Molecular Neuroscience Data Science & Digital Health, Johnson & Johnson (2022–2025) — directly managed five PhD-level scientists across the U.S. and Belgium; chaired UKB-PPP expansion; developed 'pharmacoproteomics' framework across Phase III trials; J&J Innovative Leadership Award 2023
- Associate Director & Head of Translational Genetics, Biogen (2018–2022) — conceived and secured $15M for UKB-PPP; led siRNA Alzheimer's program to portfolio entry; Biogen CEO Award 2020
- Manager, Human Genetics & Head of Scientific Strategy for Neuroscience, Pfizer (2016–2018) — genetics lead for neuroscience division; international collaborations with Lund University and 23andMe
- Chair, DATA-PD biomarkers initiative, Michael J. Fox Foundation (2024–) · Honorary Faculty, Royal College of Surgeons in Ireland (2025–) · Founder, ENIGMA-Epilepsy neuroimaging consortium
- Ph.D., Neuroscience & Statistical Genetics, RCSI · M.Sc. (Distinction), Neuroscience, Trinity College Dublin · B.A. (First Class Honours), Psychology, UCD · Postdoc, Imaging Genetics, University of Southern California
SA
Scientific leader in aging biology and translational proteomics, with a track record building multi-omics discovery platforms integrating longitudinal plasma proteomics, imaging, and machine learning. Led landmark "ageotypes" study in Nature Medicine; co-author on papers in Science, Cell, Nature, Nature Biotechnology, and Nature Communications.
- Principal Consultant, Biomarkers & Multi-Omics Strategy, OmicsEra (2025–present)
- Associate Director, Multi-Omics & Biomarker Discovery, Alkahest (2021–2025) — led 5-member cross-functional team
- Research Fellow, Google Accelerated Science (2019–2021) — developed EyeAge organ aging clock
- Postdoctoral Fellow, Mike Snyder Group, Stanford University (2015–2019)
- Active lead, Human Plasma Proteome Project
- Ph.D., Chemical Biology, University of California, Davis
DMc
Senior bioinformatics scientist with deep expertise in population-scale multi-omics, proteomics, and DNA methylation-based ageing clocks. Managed the Generation Scotland multi-omics resource and helped build one of the world's largest single-cohort DNAm datasets. Led an international consortium GWAS meta-analysis of biological ageing; published extensively on proteomic- and methylomic-based risk prediction. At bioXcelerate, leads scientific innovation in biobanks, proteomics, and large-scale omics data.
- Ph.D. Molecular Medicine (Psychiatric Genetics), University of Edinburgh
- Postdoctoral research — large-scale genetic & DNAm data applied to ageing and complex health traits
- Led Generation Scotland multi-omics resource management; developed one of the world's largest single-cohort DNAm datasets
- International consortium lead — GWAS meta-analysis of biological ageing
- Expertise: bioinformatics pipelines, multi-omics integration, statistical genetics, GWAS/pQTL/eQTL/mQTL, proteomics, ageing biology
Early-career computational proteomics scientist with hands-on experience across all major plasma proteomic platforms — directly relevant to SYN-WAVE platform evaluation and data generation. First-author on a landmark Communications Chemistry (2025) platform-comparison study benchmarking 8 proteomics platforms across 13,000+ proteins, already cited by Nature Genetics and SomaLogic. Co-author on a Science Advances pharmacology study from the Alkahest aging biology group.
- M.S. Bioengineering, University of California, Riverside (2019–2020)
- Proteomics Scientist / Analyst, Alkahest Inc. (2021–2025) — full-time member of Sara Ahadi's multi-omics group; direct prior working relationship with Synoptic CTO
- Thermo Fisher Scientific — applications / technical scientist role (~2020–2021)
- Computational Analyst, Vero Bioscience (current) — 6-person team; Synoptic's most direct proteomics competitor
- Platform expertise: SomaScan, Olink PEA, DDA/DIA mass spectrometry, Evosep/Orbitrap, LC-MS/MS; R/Python data science
DM
Oncology clinical development leader spanning major pharma and the cutting edge of liquid biopsy diagnostics — bringing exactly the clinical trial design and regulatory pathway expertise Synoptic requires.
- VP Clinical Development, DELFI Diagnostics (recently departed)
- Global Head of Clinical Development, Roche Oncology & Genetics
- Deep experience in IVD clinical development and regulatory strategy
KS
Associate Professor and Senior Molecular Epidemiologist at Oxford's Cancer Epidemiology Unit — a world-leading authority on large-scale proteomic and genetic epidemiology of cancer causation. His 2023 Nature Communications paper identifying proteomic signatures across 19 cancer types in the UK Biobank is the single closest published validation of INTEGRAL's scientific thesis.
- Co-leads Cancer Research UK programme on circulating proteins in cancer (prostate cancer focus)
- Co-leads DISCERN proteomics initiative — pancreatic, renal & colorectal cancer causation
- Chair, EPIC Genetics Working Group; Steering Committee, NCI Cohort Consortium
- Team ATLAS — international collaboration on immune-mediated cancer resistance pathways
- DPhil Population Health (Oxford); postdoc IARC Lyon; MPhil Biological Anthropology (Cambridge)
DP
25 years at the interface of biomedical mass spectrometry and proteomics — spanning academic proteomics centre leadership, pharma Exploratory Science, and biopharma consulting. Pioneer of single-cell and ultra-low-input proteomics approaches with direct translational relevance to Synoptic's organ-aging platform.
- Founder & Director, Princeton Collaborative Proteomics Center — established Princeton's proteomics infrastructure
- Director, Exploratory Proteomics, Merck Exploratory Science Center — led pharmaceutical proteomics R&D from 2018
- Co-PI with Nikolai Slavov (Northeastern) on single-cell proteomics methods; Nature Methods & Nature Protocols publications
- Co-Founder & VP Target Discovery, Crescenta Biosciences — proteomics-driven target ID in oncology
- 118 peer-reviewed publications · 4,744 citations · PhD Virology, Boston University
NL
Chief Scientific Officer and Chair of the Board of Broad Clinical Laboratories — the CLIA/CAP-certified clinical subsidiary of the Broad Institute of MIT and Harvard. The person who built the infrastructure Synoptic intends to run its INTEGRAL panel through, overseeing genomics and diagnostics operations at unparalleled scale.
- CSO & Chair, Broad Clinical Laboratories — CLIA/CAP-licensed wholly-owned Broad subsidiary
- Senior Director, Genomics Platform & Associate Director, Gerstner Center for Cancer Diagnostics
- Led FDA approval for NIH All of Us large-scale genomics programme; delivered 37M+ COVID diagnostic results
- At Broad since 2005 — built clinical genomics infrastructure across infectious disease, cancer, rare & chronic conditions
- Ph.D. Pharmacology, University College Dublin; postdoc Harvard Medical School / MGH; MIT Sloan Executive Certificate
EL
20+ years of hands-on regulatory expertise across IVDs and medical devices. As founder of EL Regulatory, brings independent practice depth across 510(k), De Novo, and global IVD pathways.
- Founder, EL Regulatory — IVD & medical device regulatory consultancy
- 20+ years in IVD regulation, 510(k) and De Novo submissions
- Global IVD regulatory strategy and EU IVDR experience
LH
25+ years turning policy complexity into federal funding and market access for life science and health technology clients. The architect of proteomics' first-ever named appropriations wins in both DoD and NIH — and the person who put Chris on CDMRP's proteomics roundtable.
- Secured Proteomics as a named DoD/CDMRP topic area for the first time in FY23 — maintained through FY26
- Led team that established the first Proteomics call-out in the LHHS/NIH Appropriations bill — FY23, FY24 & FY25
- Invited by CDMRP to convene a proteomics research & funding roundtable; tapped Chris Whelan as inaugural member
- Advancing proteomics as a national research priority with the French government; follow-up meetings Paris May/Jun 2026
Synoptic is in active discussions with tenured faculty at Stanford University, Northeastern University, and Cedars-Sinai Medical Center — each with prominent research programmes in proteomics and precision medicine — regarding formal advisory positions. Further details available on request.